GlassScriptPhysician profile
Catherine M Eldridge
NPI 1376180992
$1,528.43
in general payments reported to CMS, 2019-2025
12 companies · $935 in 2025
The $935 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $24.57 · 2023: $80.58 · 2024: $338 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Travel and Lodging: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.28 |
| Travel and Lodging | $340.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $632.46 | 2024-2025 | Urolift, Barrigel |
| Antares Pharma, INC. | $225.32 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $195.89 | 2021-2025 | Xtandi |
| Abbvie INC. | $109.61 | 2023-2025 | |
| 180 Medical, INC. | $86.95 | 2025 | Gentlecath Glide, Gentlecath |
| Endo USA, INC. | $73.71 | 2024-2025 | Xiaflex |
| Boston Scientific Corporation | $56.90 | 2024 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $42.65 | 2025 | |
| Sumitomo Pharma America, INC. | $40.53 | 2023-2024 | Gemtesa |
| Endo Pharmaceuticals INC. | $24.59 | 2021 | |
| Tolmar, INC. | $23.57 | 2025 | Eligard, Jatenzo |
| Lilly USA, LLC | $16.25 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.